<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cancers | BM Sci-Tech Memento</title>
    <link>https://example.com/tag/cancers/</link>
      <atom:link href="https://example.com/tag/cancers/index.xml" rel="self" type="application/rss+xml" />
    <description>Cancers</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Mon, 02 Jan 2023 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://example.com/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_512x512_fill_lanczos_center_3.png</url>
      <title>Cancers</title>
      <link>https://example.com/tag/cancers/</link>
    </image>
    
    <item>
      <title>Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma</title>
      <link>https://example.com/article/23-01-03-08-19/</link>
      <pubDate>Mon, 02 Jan 2023 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/23-01-03-08-19/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Enhanced glycolysis and accumulation of lactate is a common feature in various types of cancer. Intracellular lactate drives a recently described type of posttranslational modification, lysine lactylation (Kla), on core histones. However, the impact of lactylation on biological processes of tumour cells remains largely unknown. Here we show a global lactylome profiling on a prospectively collected hepatitis B virus-related hepatocellular carcinoma (HCC) cohort. Integrative lactylome and proteome analysis of the tumours and adjacent livers identifies 9,275 Kla sites, with 9,256 sites on non-histone proteins, indicating that Kla is a prevalent modification beyond histone proteins and transcriptional regulation. Notably, Kla preferentially affects enzymes involved in metabolic pathways, including the tricarboxylic acid cycle, and carbohydrate, amino acid, fatty acid and nucleotide metabolism. We further verify that lactylation at K28 inhibits the function of adenylate kinase 2, facilitating the proliferation and metastasis of HCC cells. Our study therefore reveals that Kla plays an important role in regulating cellular metabolism and may contribute to HCC progression.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>A tumor-suppressive circular RNA mediates uncanonical integrin degradation by the proteasome in liver cancer</title>
      <link>https://example.com/article/33762338/</link>
      <pubDate>Wed, 24 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/33762338/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Circular RNAs (circRNAs) have emerged as important regulators of various cellular processes and have been implicated in cancer. Previously, we reported the discovery of several dysregulated circRNAs including circPABPC1 (polyadenylate-binding protein 1) in human hepatocellular carcinoma (HCC), although their roles in HCC development remained unclear. Here, we show that circPABPC1 is preferentially lost in tumor cells from clinical samples and inhibits both intrahepatic and distant metastases in a mouse xenograft model. This tumor-suppressive function of circPABPC1 can be attributed to its inhibition of cell adhesion and migration through down-regulating a key member of the integrin family, ITGB1 (Î²&lt;sub&gt;1&lt;/sub&gt; integrin). Mass spectrometry and biochemical evidence demonstrate that circPABPC1 directly links ITGB1 to the 26S proteasome for degradation in a ubiquitination-independent manner. Our data have revealed an uncanonical route for integrin turnover and a previously unidentified mode of action for circRNAs in HCC that can be harnessed for anticancer&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>miRNA-mediated loss of m6A increases nascent translation in glioblastoma</title>
      <link>https://example.com/article/33684100/</link>
      <pubDate>Mon, 08 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/33684100/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Within the glioblastoma cellular niche, glioma stem cells (GSCs) can give rise to differentiated glioma cells (DGCs) and, when necessary, DGCs can reciprocally give rise to GSCs to maintain the cellular equilibrium necessary for optimal tumor growth. Here, using ribosome profiling, transcriptome and m&lt;sup&gt;6&lt;/sup&gt;A RNA sequencing, we show that GSCs from patients with different subtypes of glioblastoma share a set of transcripts, which exhibit a pattern of m&lt;sup&gt;6&lt;/sup&gt;A loss and increased protein translation during differentiation. The target sequences of a group of miRNAs overlap the canonical RRACH m&lt;sup&gt;6&lt;/sup&gt;A motifs of these transcripts, many of which confer a survival advantage in glioblastoma. Ectopic expression of the RRACH-binding miR-145 induces loss of m&lt;sup&gt;6&lt;/sup&gt;A, formation of FTO/AGO1/ILF3/miR-145 complexes on a clinically relevant tumor suppressor gene (CLIP3) and significant increase in its nascent translation. Inhibition of miR-145 maintains RRACH m&lt;sup&gt;6&lt;/sup&gt;A levels of CLIP3 and inhibits its nascent translation. This study highlights a critical role of miRNAs in assembling complexes for m&lt;sup&gt;6&lt;/sup&gt;A demethylation and induction of protein translation during GSC state transition.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer</title>
      <link>https://example.com/article/33664238/</link>
      <pubDate>Fri, 05 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/33664238/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Alternative splicing is a critical process to generate protein diversity. However, whether and how alternative splicing regulates autophagy remains largely elusive. Here we systematically identify the splicing factor SRSF1 as an autophagy suppressor. Specifically, SRSF1 inhibits autophagosome formation by reducing the accumulation of LC3-II and numbers of autophagosomes in different cell lines. Mechanistically, SRSF1 promotes the splicing of the long isoform of Bcl-x that interacts with Beclin1, thereby dissociating the Beclin1-PIK3C3 complex. In addition, SRSF1 also directly interacts with PIK3C3 to disrupt the interaction between Beclin1 and PIK3C3. Consequently, the decrease of SRSF1 stabilizes the Beclin1 and PIK3C3 complex and activates autophagy. Interestingly, SRSF1 can be degraded by starvation- and oxidative stresses-induced autophagy through interacting with LC3-II, whereas reduced SRSF1 further promotes autophagy. This positive feedback is critical to inhibiting Gefitinib-resistant cancer cell progression both in vitro and in vivo. Consistently, the expression level of SRSF1 is inversely correlated to LC3 level in clinical cancer samples. Our study not only provides mechanistic insights of alternative splicing in autophagy regulation but also discovers a new regulatory role of SRSF1 in tumorigenesis, thereby offering a novel avenue for potential cancer therapeutics.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer</title>
      <link>https://example.com/article/33288768/</link>
      <pubDate>Mon, 07 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/33288768/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;In the colon, long-term exposure to chronic inflammation drives colitis-associated colon cancer (CAC) in patients with inflammatory bowel disease. While the causal and clinical links are well established, molecular understanding of how chronic inflammation leads to the development of colon cancer is lacking. Here we deconstruct the evolving microenvironment of CAC by measuring proteomic changes and extracellular matrix (ECM) organization over time in a mouse model of CAC. We detect early changes in ECM structure and composition, and report a crucial role for the transcriptional regulator heat shock factor 1 (HSF1) in orchestrating these events. Loss of HSF1 abrogates ECM assembly by colon fibroblasts in cell-culture, prevents inflammation-induced ECM remodeling in mice and inhibits progression to CAC. Establishing relevance to human disease, we find high activation of stromal HSF1 in CAC patients, and detect the HSF1-dependent proteomic ECM signature in human colorectal cancer. Thus, HSF1-dependent ECM remodeling plays a crucial role in mediating inflammation-driven colon cancer.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Transcriptome-wide profiles of circular RNA and RNA-binding protein interactions reveal effects on circular RNA biogenesis and cancer pathway expression</title>
      <link>https://example.com/article/33287884/</link>
      <pubDate>Mon, 07 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/33287884/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Background:&lt;/em&gt; Circular RNAs (circRNAs) are stable, often highly expressed RNA transcripts with potential to modulate other regulatory RNAs. A few circRNAs have been shown to bind RNA-binding proteins (RBPs); however, little is known about the prevalence and distribution of these interactions in different biological contexts.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Methods:&lt;/em&gt; We conduct an extensive screen of circRNA-RBP interactions in the ENCODE cell lines HepG2 and K562. We profile circRNAs in deep-sequenced total RNA samples and analyze circRNA-RBP interactions using a large set of eCLIP data with binding sites of 150 RBPs. We validate interactions for select circRNAs and RBPs by performing RNA immunoprecipitation and functionally characterize our most interesting candidates by conducting knockdown studies followed by RNA-Seq.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Results:&lt;/em&gt; We generate a comprehensive catalog of circRNA-RBP interactions in HepG2 and K562 cells. We show that KHSRP binding sites are enriched in flanking introns of circRNAs and that KHSRP depletion affects circRNA biogenesis. We identify circRNAs that are highly covered by RBP binding sites and experimentally validate individual circRNA-RBP interactions. We show that circCDYL, a highly expressed circRNA with clinical and functional implications in bladder cancer, is almost completely covered with GRWD1 binding sites in HepG2 cells, and that circCDYL depletion counteracts the effect of GRWD1 depletion. Furthermore, we confirm interactions between circCDYL and RBPs in bladder cancer cells and demonstrate that circCDYL depletion affects hallmarks of cancer and perturbs the expression of key cancer genes, e.g., TP53. Finally, we show that elevated levels of circCDYL are associated with overall survival of bladder cancer patients.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Conclusions:&lt;/em&gt; Our study demonstrates transcriptome-wide and cell-type-specific circRNA-RBP interactions that could play important regulatory roles in tumorigenesis.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Comprehensive databases for biomedical research</title>
      <link>https://example.com/tool/db-biomed-res/</link>
      <pubDate>Wed, 02 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/tool/db-biomed-res/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;https://db.cngb.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;China National GeneBank DataBase (CNGBdb)&lt;/strong&gt;&lt;/a&gt; is a uniï¬ed platform built for biological big data sharing and application services to the research community. Based on the big data and cloud computing technologies, it provides data services such as archive, analysis, knowledge search, management authorization, and visualization.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;National Center for Biotechnology Information (NCBI)&lt;/strong&gt;&lt;/a&gt; advances science and health by providing access to biomedical and genomic information.
&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;PubMed&lt;/em&gt;&lt;/a&gt; comprises more than 34 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text content from PubMed Central and publisher web sites.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/gene/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;Gene&lt;/em&gt;&lt;/a&gt; supplies gene-specific connections in the nexus of map, sequence, expression, structure, function, citation, and homology data. Unique identifiers are assigned to genes with defining sequences, genes with known map positions, and genes inferred from phenotypic information.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/nuccore/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;Nucleotide&lt;/em&gt;&lt;/a&gt; deposites DNA and RNA sequences.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;Gene Expression Omnibus (GEO)&lt;/em&gt;&lt;/a&gt;  is a public functional genomics data repository supporting MIAME-compliant data submissions. Array- and sequence-based data are accepted. Tools are provided to help users query and download experiments and curated gene expression profiles. Users can also analyze published data to identify genes that are differentially expressed across experimental conditions with &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/geo2r/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GEO2R&lt;/a&gt;, where codes and scripts are not needed.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://blast.ncbi.nlm.nih.gov/Blast.cgi&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;Basic Local Alignment Search Tool (BLAST)&lt;/em&gt;&lt;/a&gt; finds regions of similarity between biological sequences. The program compares nucleotide or protein sequences to sequence databases and calculates the statistical significance.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://www.ebi.ac.uk/biostudies/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;BioStudies&lt;/strong&gt;&lt;/a&gt; holds descriptions of biological studies, links to data from these studies in other databases at &lt;a href=&#34;https://www.ebi.ac.uk/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;EMBL-EBI&lt;/a&gt; or outside, as well as data that do not fit in the structured archives at &lt;a href=&#34;https://www.ebi.ac.uk/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;EMBL-EBI&lt;/a&gt;. The database accepts submissions via an online tool, or in a simple tab-delimited format. It also enables authors to submit supplementary information and link to it from the publication.
&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;https://www.ebi.ac.uk/biostudies/arrayexpress&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;ArrayExpress&lt;/em&gt;&lt;/a&gt;, the functional genomics collection, stores data from high-throughput functional genomics experiments, and provides data for reuse to the research community. In line with community guidelines, a study typically contains metadata such as detailed sample annotations, protocols, processed data and raw data. Raw sequence reads from high-throughput sequencing studies are brokered to the European Nucleotide Archive (ENA), and links are provided to download the sequence reads from ENA. Data can be submitted to the &lt;a href=&#34;https://www.ebi.ac.uk/biostudies/arrayexpress&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;ArrayExpress&lt;/em&gt;&lt;/a&gt; collection through its dedicated submission tool, Annotare.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Genomes&lt;/strong&gt;
&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;https://www.ensembl.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;Ensembl&lt;/em&gt;&lt;/a&gt; is a genome browser for vertebrate genomes that supports research in comparative genomics, evolution, sequence variation and transcriptional regulation and a part of the &lt;a href=&#34;https://elixir-europe.org/platforms/data/core-data-resources&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;ELIXIR Core Data Resources&lt;/a&gt;.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;http://www.genome.ucsc.edu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;The UCSC Genome Browser&lt;/em&gt;&lt;/a&gt; is a web-based tool serving as a multi-powered microscope that allows researchers to view all 23 chromosomes of the human genome at any scale from a full chromosome down to an individual nucleotide.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://www.gencodegenes.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;GENCODE&lt;/em&gt;&lt;/a&gt; aims to identify and classify all gene features in the human and mouse genomes with high accuracy based on biological evidence, and to release these annotations for the benefit of biomedical research and genome interpretation.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;http://www.noncode.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;NONCODE&lt;/em&gt;&lt;/a&gt; is an integrated knowledge database dedicated to non-coding RNAs (excluding tRNAs and rRNAs). The source of &lt;a href=&#34;http://www.noncode.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;NONCODE&lt;/em&gt;&lt;/a&gt; includes literature and other public databases. &lt;a href=&#34;http://www.noncode.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;NONCODE&lt;/em&gt;&lt;/a&gt; searches PubMed using key words &lt;code&gt;ncrna&lt;/code&gt;, &lt;code&gt;noncoding&lt;/code&gt;, &lt;code&gt;non-coding&lt;/code&gt;, &lt;code&gt;no code&lt;/code&gt;, &lt;code&gt;non-code&lt;/code&gt;, &lt;code&gt;lncrna&lt;/code&gt; or &lt;code&gt;lincrna&lt;/code&gt;. NONCODE retrieves the new identified lncRNAs and their annotation from the Supplementary Material or web site of these articles. Together with the newest data from &lt;a href=&#34;https://www.ensembl.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Ensembl&lt;/a&gt;, &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/refseq/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;RefSeq&lt;/a&gt;, &lt;a href=&#34;http://lncrnadb.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;lncRNAdb&lt;/a&gt; and &lt;a href=&#34;https://www.gencodegenes.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GENCODE&lt;/a&gt; were processed through a standard pipeline for each species.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://www.encodeproject.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;Encyclopedia of DNA Elements (ENCODE)&lt;/em&gt;&lt;/a&gt; Consortium is an ongoing international collaboration of research groups funded by the National Human Genome Research Institute (NHGRI). The goal of &lt;a href=&#34;https://www.encodeproject.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;ENCODE&lt;/em&gt;&lt;/a&gt; is to build a comprehensive parts list of functional elements in the human genome, including elements that act at the protein and RNA levels, and regulatory elements that control cells and circumstances in which a gene is active.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Cancers&lt;/strong&gt;
&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;The Cancer Genome Atlas (TCGA)&lt;/em&gt;&lt;/a&gt;, a landmark cancer genomics program, molecularly characterizes over 20,000 primary cancer and matched normal samples spanning 33 cancer types. Usually, we prefer to access the Database via &lt;a href=&#34;https://portal.gdc.cancer.gov/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Genomic Data Commons Data Portal (GDC)&lt;/a&gt;.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://www.cbioportal.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;cBioPortal&lt;/em&gt;&lt;/a&gt; for Cancer Genomics was originally developed at &lt;a href=&#34;https://www.mskcc.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Memorial Sloan Kettering Cancer Center (MSKCC)&lt;/a&gt;. The public &lt;a href=&#34;https://www.cbioportal.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;cBioPortal&lt;/em&gt;&lt;/a&gt; site is hosted by the Center for &lt;a href=&#34;https://www.mskcc.org/research-programs/molecular-oncology&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Molecular Oncology&lt;/a&gt; at &lt;a href=&#34;https://www.mskcc.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;MSKCC&lt;/a&gt;. The &lt;a href=&#34;https://www.cbioportal.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;cBioPortal&lt;/em&gt;&lt;/a&gt; software is now available under an open source license via &lt;a href=&#34;https://github.com/cBioPortal/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GitHub&lt;/a&gt; 
  &lt;i class=&#34;fab fa-github  pr-1 fa-fw&#34;&gt;&lt;/i&gt;.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;http://gepia2.cancer-pku.cn/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;GEPIA&lt;/em&gt;&lt;/a&gt; is for analyzing the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from the &lt;a href=&#34;https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;TCGA&lt;/a&gt; and the &lt;a href=&#34;https://www.gtexportal.org/home&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GTEx&lt;/a&gt; projects, using a standard processing pipeline. &lt;a href=&#34;http://gepia2.cancer-pku.cn/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;GEPIA&lt;/em&gt;&lt;/a&gt; provides customizable functions such as tumor/normal differential expression analysis, profiling according to cancer types or pathological stages, patient survival analysis, similar gene detection, correlation analysis and dimensionality reduction analysis.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;http://xena.ucsc.edu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;UCSC Xena&lt;/em&gt;&lt;/a&gt; allows users to explore functional genomic data sets for correlations between genomic and/or phenotypic variables. It provides interactive online visualization of seminal cancer genomics datasets, including data from &lt;a href=&#34;https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;(TCGA)&lt;/a&gt;, &lt;a href=&#34;https://dcc.icgc.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;International Cancer Genome Consortium (ICGC)&lt;/a&gt;, and &lt;a href=&#34;https://gdc.cancer.gov/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Genomic Data Commons (GDC)&lt;/a&gt;. &lt;a href=&#34;http://xena.ucsc.edu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;UCSC Xena&lt;/em&gt;&lt;/a&gt; also visualizes the UCSC RNA-seq compendium which contains data from &lt;a href=&#34;https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;TCGA&lt;/a&gt; tumor samples, &lt;a href=&#34;https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;TCGA&lt;/a&gt; normal samples, and &lt;a href=&#34;https://www.gtexportal.org/home&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GTEx&lt;/a&gt; normal samples. &lt;a href=&#34;http://xena.ucsc.edu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;UCSC Xena&lt;/em&gt;&lt;/a&gt; supports virtually any functional genomics data, including SNVs, INDELs, large structural variants, copy number variation, gene-, transcript-, exon-, miRNA-, LncRNA-, protein-expressions, DNA methylation, ATAC-seq signals, phenotypic/clinical annotations, and higher-level derived genomic parameters.&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://gdac.broadinstitute.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;Broad GDAC&lt;/em&gt;&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;/ul&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/tag/databases/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Databases&lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/tool/&#34; &gt;
      Alternative to Tools &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>microRNA-199a-3p inhibits hepatic apoptosis and hepatocarcinogenesis by targeting PDCD4</title>
      <link>https://example.com/article/33099584/</link>
      <pubDate>Sat, 24 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/33099584/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Hepatic apoptosis and the initiated liver inflammation play the initial roles in inflammation-induced hepatocarcinogenesis. Molecular mechanisms underlying the regulation of hepatocyte apoptosis and their roles in hepatocarcinogenesis have attracted much attention. A set of microRNAs (miRNAs) have been determined to be dysregulated in hepatocellular carcinoma (HCC) and participated in cancer progression, however, the roles of these dysregulated miRNAs in carcinogenesis are still poorly understood. We previously analyzed the dysregulated miRNAs in HCC using high-throughput sequencing, and found that miR-199a/b-3p was abundantly expressed in human normal liver while markedly decreased in HCC, which promotes HCC progression. Whether miR-199a/b-3p participates in HCC carcinogenesis is still unknown up to now. Hence, we focused on the role and mechanism of miR-199a/b-3p in hepatocarcinogenesis in this study. Hepatic miR-199a/b-3p was determined to be expressed by miR-199a-2 gene in mice, and we constructed miR-199a-2 knockout and hepatocyte-specific miR-199a-2 knockout mice. Diethylnitrosamine (DEN)-induced hepatocarcinogenesis were markedly increased by hepatocyte-specific miR-199a-3p knockout, which is mediated by the enhanced hepatocyte apoptosis and hepatic injury by DEN administration. In acetaminophen (APAP)-induced acute hepatic injury model, hepatocyte-specific miR-199a-3p knockout also aggravated hepatic apoptosis. By proteomic screening and reporter gene validation, we identified and verified that hepatic programed cell death 4 (PDCD4), which promotes apoptosis, was directly targeted by miR-199a-3p. Furthermore, we confirmed that miR-199a-3p-suppressed hepatocyte apoptosis and hepatic injury by targeting and suppressing PDCD4. Thus, hepatic miR-199a-3p inhibits hepatocyte apoptosis and hepatocarcinogenesis, and decreased miR-199a-3p in hepatocytes may aggravate hepatic injury and HCC development.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>TSPAN1 promotes autophagy flux and mediates cooperation between WNT-CTNNB1 signaling and autophagy via the MIR454-FAM83A-TSPAN1 axis in pancreatic cancer</title>
      <link>https://example.com/article/32972302/</link>
      <pubDate>Thu, 22 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/32972302/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Pancreatic cancer is one of the most aggressive tumors associated with a poor clinical prognosis, weakly effective therapeutic options. Therefore, there is a strong impetus to discover new therapeutic targets in pancreatic cancer. In the present study, we first demonstrated that TSPAN1 is upregulated in pancreatic cancer and that TSPAN1 depletion decreases pancreatic cancer cell proliferation in vitro and in vivo. TSPAN1 expression was correlated with poor overall survival of pancreatic cancer patients. Moreover, we demonstrated that TSPAN1 is a novel positive regulator of macroautophagy/autophagy characterized by decreased LC3-II and SQSTM1/p62 expressions, inhibited puncta formation of GFP-LC3 and autophagic vacuoles. We also demonstrated that tspan1 mutation impaired autophagy in the zebrafish model. Furthermore, we showed that TSPAN1 promoted autophagy maturation via direct binding to LC3 by two conserved LIR motifs. Mutations in the LIR motifs of TSPAN1 resulted in a loss of the ability to induce autophagy and promote pancreatic cancer proliferation. Second, we discovered two conservative TCF/LEF binding elements present in the promoter region of the TSPAN1 gene, which was further verified through luciferase activity and ChIP assays. Furthermore, TSPAN1 was upregulated by FAM83A through the canonical WNT-CTNNB1 signaling pathway. We further demonstrated that both TSPAN1 and FAM83A are both direct targets of MIR454 (microRNA 454). Additionally, we revealed the role of MIR454-FAM83A-TSPAN1 in the proliferation of pancreatic cancer cells in vitro and in vivo. Our findings suggest that components of the MIR454-FAM83A-TSPAN1 axis may be valuable prognosis markers or therapeutic targets for pancreatic cancer.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>PIWIL1 promotes gastric cancer via a piRNA-independent mechanism</title>
      <link>https://example.com/article/32848063/</link>
      <pubDate>Wed, 26 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/32848063/</guid>
      <description>&lt;blockquote&gt;
&lt;p&gt;&lt;strong&gt;&lt;em&gt;Erratum in:&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Correction for Shi &lt;em&gt;et al.&lt;/em&gt;, &lt;a href=&#34;https://www.pnas.org/doi/full/10.1073/pnas.2019929117&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;PIWIL1 promotes gastric cancer via a piRNA-independent mechanism&lt;/em&gt;&lt;/a&gt;.&lt;/p&gt;
&lt;/blockquote&gt;
&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Targeted cancer therapy aims to achieve specific elimination of cancerous but not normal cells. Recently, PIWI proteins, a subfamily of the PAZ-PIWI domain (PPD) protein family, have emerged as promising candidates for targeted cancer therapy. PPD proteins are essential for small noncoding RNA pathways. The Argonaute subfamily partners with microRNA and small interfering RNA, whereas the PIWI subfamily partners with PIWI-interacting RNA (piRNA). Both PIWI proteins and piRNA are mostly expressed in the germline and best known for their function in transposon silencing, with no detectable function in mammalian somatic tissues. However, PIWI proteins become aberrantly expressed in multiple types of somatic cancers, thus gaining interest in targeted therapy. Despite this, little is known about the regulatory mechanism of PIWI proteins in cancer. Here we report that one of the four PIWI proteins in humans, PIWIL1, is highly expressed in gastric cancer tissues and cell lines. Knocking out the PIWIL1 gene (&lt;em&gt;PIWIL1-KO&lt;/em&gt;) drastically reduces gastric cancer cell proliferation, migration, metastasis, and tumorigenesis. RNA deep sequencing of gastric cancer cell line SNU-1 reveals that KO significantly changes the transcriptome, causing the up-regulation of most of its associated transcripts. Surprisingly, few bona fide piRNAs exist in gastric cancer cells. Furthermore, abolishing the piRNA-binding activity of PIWIL1 does not affect its oncogenic function. Thus, PIWIL1 function in gastric cancer cells is independent of piRNA. This piRNA-independent regulation involves interaction with the UPF1-mediated nonsense-mediated mRNA decay (NMD) mechanism. Altogether, our findings reveal a piRNA-independent function of PIWIL1 in promoting gastric cancer.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination</title>
      <link>https://example.com/article/32807901/</link>
      <pubDate>Mon, 17 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/32807901/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;p53 is the most intensively studied tumour suppressor. The regulation of p53 homeostasis is essential for its tumour-suppressive function. Although p53 is regulated by an array of post-translational modifications, both during normal homeostasis and in stress-induced responses, how p53 maintains its homeostasis remains unclear. UFMylation is a recently identified ubiquitin-like modification with essential biological functions. Deficiency in this modification leads to embryonic lethality in mice and disease in humans. Here, we report that p53 can be covalently modified by UFM1 and that this modification stabilizes p53 by antagonizing its ubiquitination and proteasome degradation. Mechanistically, UFL1, the UFM1 ligase, competes with MDM2 to bind to p53 for its stabilization. Depletion of UFL1 or DDRGK1, the critical regulator of UFMylation6,13, decreases p53 stability and in turn promotes cell growth and tumour formation in vivo. Clinically, UFL1 and DDRGK1 expression are downregulated and positively correlated with levels of p53 in a high percentage of renal cell carcinomas. Our results identify UFMylation as a crucial post-translational modification for maintenance of p53 stability and tumour-suppressive function, and point to UFMylation as a promising therapeutic target in cancer.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/Î²-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes</title>
      <link>https://example.com/article/32727463/</link>
      <pubDate>Wed, 29 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/32727463/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Background:&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Pancreatic cancer is one of the most lethal malignancies and has an extremely poor diagnosis and prognosis. The development of resistance to gemcitabine is still a major challenge. The long noncoding RNA PVT1 was reported to be involved in carcinogenesis and chemoresistance; however, the mechanism by which PVT1 regulates the sensitivity of pancreatic cancer to gemcitabine remains poorly understood.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Methods:&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;The viability of pancreatic cancer cells was assessed by MTT assay in vitro and xenograft tumor formation assay in vivo. The expression levels of PVT1 and miR-619-5p were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Western blotting analysis and qRT-PCR were performed to assess the protein and mRNA levels of Pygo2 and ATG14, respectively. Autophagy was explored via autophagic flux detection under confocal microscopy and autophagic vacuole investigation under transmission electron microscopy (TEM). The functional role and mechanism of PVT1 were further investigated by gain- and loss-of-function assays in vitro.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Results:&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;In the present study, we demonstrated that PVT1 was up-regulated in gemcitabine-resistant pancreatic cancer cell lines. Gain- and loss-of-function assays revealed that PVT1 impaired sensitivity to gemcitabine in vitro and in vivo. We further found that PVT1 up-regulated the expression of both Pygo2 and ATG14 and thus regulated Wnt/Î²-catenin signaling and autophagic activity to overcome gemcitabine resistance through sponging miR-619-5p. Moreover, we discovered three TCF/LEF binding elements (TBEs) in the promoter region of PVT1, and activation of Wnt/Î²-catenin signaling mediated by the up-regulation of Pygo2 increased PVT1 expression by direct binding to the TBE region. Furthermore, PVT1 was discovered to interact with ATG14, thus promoting assembly of the autophagy specific complex I (PtdIns3K-C1) and ATG14-dependent class III PtdIns3K activity.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Conclusions:&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;These data indicate that PVT1 plays a critical role in the sensitivity of pancreatic cancer to gemcitabine and highlight its potential as a valuable target for pancreatic cancer therapy.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice</title>
      <link>https://example.com/article/32581213/</link>
      <pubDate>Wed, 24 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/32581213/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Breast cancer is the most common type of cancer worldwide and one of the major causes of cancer death in women. Epidemiological studies have established a link between night-shift work and increased cancer risk, suggesting that circadian disruption may play a role in carcinogenesis. Here, we aim to shed light on the effect of chronic jetlag (JL) on mammary tumour development. To do this, we use a mouse model of spontaneous mammary tumourigenesis and subject it to chronic circadian disruption. We observe that circadian disruption significantly increases cancer-cell dissemination and lung metastasis. It also enhances the stemness and tumour-initiating potential of tumour cells and creates an immunosuppressive shift in the tumour microenvironment. Finally, our results suggest that the use of a CXCR2 inhibitor could correct the effect of JL on cancer-cell dissemination and metastasis. Altogether, our data provide a conceptual framework to better understand and manage the effects of chronic circadian disruption on breast cancer progression.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer</title>
      <link>https://example.com/article/32554929/</link>
      <pubDate>Thu, 18 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/32554929/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Interferon regulatory factor 1 (IRF1) regulates diverse biological functions, including modulation of cellular responses involved in tumorigenesis. Genetic mutations and altered IRF1 function are associated with several cancers. Although the function of IRF1 in the immunobiology of cancer is emerging, IRF1-specific mechanisms regulating tumorigenesis and tissue homeostasis in vivo are not clear. Here, we found that mice lacking IRF1 were hypersusceptible to colorectal tumorigenesis. IRF1 functions in both the myeloid and epithelial compartments to confer protection against AOM/DSS-induced colorectal tumorigenesis. We further found that IRF1 also prevents tumorigenesis in a spontaneous mouse model of colorectal cancer. The attenuated cell death in the colons of Irf1-/- mice was due to defective pyroptosis, apoptosis, and necroptosis (PANoptosis). IRF1 does not regulate inflammation and the inflammasome in the colon. Overall, our study identified IRF1 as an upstream regulator of PANoptosis to induce cell death during colitis-associated tumorigenesis.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>c-Rel Is a Myeloid Checkpoint for Cancer Immunotherapy</title>
      <link>https://example.com/article/33458695/</link>
      <pubDate>Mon, 18 May 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/33458695/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Therapy that targets lymphoid cell checkpoints holds great promise for curing cancer. However, a majority of cancer patients do not respond to this form of therapy. In addition to lymphoid cells, myeloid cells play essential roles in controlling immunity to cancer. Whether myeloid checkpoints exist that can be targeted to treat cancer is not well established. Here we show that c-Rel, a member of the nuclear factor (NF)-B family, specified the generation of myeloid-derived suppressor cells (MDSCs) by selectively turning on pro-tumoral genes while switching off anti-tumoral genes through a c-Rel enhanceosome. c-Rel deficiency in myeloid cells markedly inhibited cancer growth in mice, and pharmaceutical inhibition of c-Rel had the same effect. Combination therapy that blocked both c-Rel and the lymphoid checkpoint protein PD1 was more effective in treating cancer than blocking either alone. Thus, c-Rel is a myeloid checkpoint that can be targeted for treating cancer.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors</title>
      <link>https://example.com/article/32405062/</link>
      <pubDate>Mon, 11 May 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/32405062/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade</title>
      <link>https://example.com/article/32405063/</link>
      <pubDate>Mon, 11 May 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/32405063/</guid>
      <description>&lt;blockquote&gt;
&lt;p&gt;&lt;strong&gt;&lt;em&gt;Erratum in:&lt;/em&gt;&lt;/strong&gt; can also be found.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Author Correction: &lt;a href=&#34;https://www.nature.com/articles/s41591-021-01246-4&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade&lt;/a&gt;&lt;/em&gt;.&lt;/p&gt;
&lt;/blockquote&gt;
&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Although elevated plasma interleukin-8 (pIL-8) has been associated with poor outcome to immune checkpoint blockade 1, this has not been comprehensively evaluated in large randomized studies. Here we analyzed circulating pIL-8 and IL8 gene expression in peripheral blood mononuclear cells and tumors of patients treated with atezolizumab (anti-PD-L1 monoclonal antibody) from multiple randomized trials representing 1,445 patients with metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma. High levels of IL-8 in plasma, peripheral blood mononuclear cells and tumors were associated with decreased efficacy of atezolizumab in patients with mUC and metastatic renal cell carcinoma, even in tumors that were classically CD8+ T cell inflamed. Low baseline pIL-8 in patients with mUC was associated with increased response to atezolizumab and chemotherapy. Patients with mUC who experienced on-treatment decreases in pIL-8 exhibited improved overall survival when treated with atezolizumab but not with chemotherapy. Single-cell RNA sequencing of the immune compartment showed that IL8 is primarily expressed in circulating and intratumoral myeloid cells and that high IL8 expression is associated with downregulation of the antigen-presentation machinery. Therapies that can reverse the impacts of IL-8-mediated myeloid inflammation will be essential for improving outcomes of patients treated with immune checkpoint inhibitors.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I</title>
      <link>https://example.com/article/32376951/</link>
      <pubDate>Wed, 22 Apr 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/32376951/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Immune evasion is a major obstacle for cancer treatment. Common mechanisms of evasion include impaired antigen presentation caused by mutations or loss of heterozygosity of the major histocompatibility complex class I (MHC-I), which has been implicated in resistance to immune checkpoint blockade (ICB) therapy. However, in pancreatic ductal adenocarcinoma (PDAC), which is resistant to most therapies including ICB, mutations that cause loss of MHC-I are rarely found despite the frequent downregulation of MHC-I expression. Here we show that, in PDAC, MHC-I molecules are selectively targeted for lysosomal degradation by an autophagy-dependent mechanism that involves the autophagy cargo receptor NBR1. PDAC cells display reduced expression of MHC-I at the cell surface and instead demonstrate predominant localization within autophagosomes and lysosomes. Notably, inhibition of autophagy restores surface levels of MHC-I and leads to improved antigen presentation, enhanced anti-tumour T cell responses and reduced tumour growth in syngeneic host mice. Accordingly, the anti-tumour effects of autophagy inhibition are reversed by depleting CD8&lt;sup&gt;+&lt;/sup&gt; T cells or reducing surface expression of MHC-I. Inhibition of autophagy, either genetically or pharmacologically with chloroquine, synergizes with dual ICB therapy (anti-PD1 and anti-CTLA4 antibodies), and leads to an enhanced anti-tumour immune response. Our findings demonstrate a role for enhanced autophagy or lysosome function in immune evasion by selective targeting of MHC-I molecules for degradation, and provide a rationale for the combination of autophagy inhibition and dual ICB therapy as a therapeutic strategy against PDAC.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>A bioorthogonal system reveals antitumour immune function of pyroptosis</title>
      <link>https://example.com/article/32188939/</link>
      <pubDate>Wed, 11 Mar 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/32188939/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Bioorthogonal chemistry capable of operating in live animals is needed to investigate biological processes such as cell death and immunity. Recent studies have identified a gasdermin family of pore-forming proteins that executes inflammasome-dependent and -independent pyroptosis. Pyroptosis is proinflammatory, but its effect on antitumour immunity is unknown. Here we establish a bioorthogonal chemical system, in which a cancer-imaging probe phenylalanine trifluoroborate (Phe-BF&lt;sub&gt;3&lt;/sub&gt;) that can enter cells desilylates and &amp;lsquo;cleaves&amp;rsquo; a designed linker that contains a silyl ether. This system enabled the controlled release of a drug from an antibody-drug conjugate in mice. When combined with nanoparticle-mediated delivery, desilylation catalysed by Phe-BF&lt;sub&gt;3&lt;/sub&gt; could release a client protein-including an active gasdermin-from a nanoparticle conjugate, selectively into tumour cells in mice. We applied this bioorthogonal system to gasdermin, which revealed that pyroptosis of less than 15% of tumour cells was sufficient to clear the entire 4T1 mammary tumour graft. The tumour regression was absent in immune-deficient mice or upon T cell depletion, and was correlated with augmented antitumour immune responses. The injection of a reduced, ineffective dose of nanoparticle-conjugated gasdermin along with Phe-BF&lt;sub&gt;3&lt;/sub&gt; sensitized 4T1 tumours to anti-PD1 therapy. Our bioorthogonal system based on Phe-BF&lt;sub&gt;3&lt;/sub&gt; desilylation is therefore a powerful tool for chemical biology; our application of this system suggests that pyroptosis-induced inflammation triggers robust antitumour immunity and can synergize with checkpoint blockade.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Databases make cancer research easier</title>
      <link>https://example.com/tool/2020-02-22-dtb-cancer-res/</link>
      <pubDate>Sat, 22 Feb 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/tool/2020-02-22-dtb-cancer-res/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;The Cancer Genome Atlas (TCGA)&lt;/em&gt;&lt;/a&gt;, a landmark cancer genomics program, molecularly characterizes over 20,000 primary cancer and matched normal samples spanning 33 cancer types. Usually, we prefer to access the Database via &lt;a href=&#34;https://portal.gdc.cancer.gov/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Genomic Data Commons Data Portal (GDC)&lt;/a&gt;.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://www.cbioportal.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;cBioPortal&lt;/em&gt;&lt;/a&gt; for Cancer Genomics was originally developed at &lt;a href=&#34;https://www.mskcc.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Memorial Sloan Kettering Cancer Center (MSKCC)&lt;/a&gt;. The public &lt;a href=&#34;https://www.cbioportal.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;cBioPortal&lt;/em&gt;&lt;/a&gt; site is hosted by the Center for &lt;a href=&#34;https://www.mskcc.org/research-programs/molecular-oncology&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Molecular Oncology&lt;/a&gt; at &lt;a href=&#34;https://www.mskcc.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;MSKCC&lt;/a&gt;. The &lt;a href=&#34;https://www.cbioportal.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;cBioPortal&lt;/em&gt;&lt;/a&gt; software is now available under an open source license via &lt;a href=&#34;https://github.com/cBioPortal/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GitHub&lt;/a&gt; 
  &lt;i class=&#34;fab fa-github  pr-1 fa-fw&#34;&gt;&lt;/i&gt;.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;http://gepia2.cancer-pku.cn/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;GEPIA&lt;/em&gt;&lt;/a&gt; is for analyzing the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from the &lt;a href=&#34;https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;TCGA&lt;/a&gt; and the &lt;a href=&#34;https://www.gtexportal.org/home&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GTEx&lt;/a&gt; projects, using a standard processing pipeline. &lt;a href=&#34;http://gepia2.cancer-pku.cn/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;GEPIA&lt;/em&gt;&lt;/a&gt; provides customizable functions such as tumor/normal differential expression analysis, profiling according to cancer types or pathological stages, patient survival analysis, similar gene detection, correlation analysis and dimensionality reduction analysis.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;http://xena.ucsc.edu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;UCSC Xena&lt;/em&gt;&lt;/a&gt; allows users to explore functional genomic data sets for correlations between genomic and/or phenotypic variables. It provides interactive online visualization of seminal cancer genomics datasets, including data from &lt;a href=&#34;https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;(TCGA)&lt;/a&gt;, &lt;a href=&#34;https://dcc.icgc.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;International Cancer Genome Consortium (ICGC)&lt;/a&gt;, and &lt;a href=&#34;https://gdc.cancer.gov/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Genomic Data Commons (GDC)&lt;/a&gt;. &lt;a href=&#34;http://xena.ucsc.edu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;UCSC Xena&lt;/em&gt;&lt;/a&gt; also visualizes the UCSC RNA-seq compendium which contains data from &lt;a href=&#34;https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;TCGA&lt;/a&gt; tumor samples, &lt;a href=&#34;https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;TCGA&lt;/a&gt; normal samples, and &lt;a href=&#34;https://www.gtexportal.org/home&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GTEx&lt;/a&gt; normal samples. &lt;a href=&#34;http://xena.ucsc.edu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;UCSC Xena&lt;/em&gt;&lt;/a&gt; supports virtually any functional genomics data, including SNVs, INDELs, large structural variants, copy number variation, gene-, transcript-, exon-, miRNA-, LncRNA-, protein-expressions, DNA methylation, ATAC-seq signals, phenotypic/clinical annotations, and higher-level derived genomic parameters.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://gdac.broadinstitute.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;Broad GDAC&lt;/em&gt;&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/tag/databases/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Databases&lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/tool/&#34; &gt;
      Alternative to Tools &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours</title>
      <link>https://example.com/article/31942068/</link>
      <pubDate>Wed, 15 Jan 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/31942068/</guid>
      <description>&lt;blockquote&gt;
&lt;p&gt;&lt;strong&gt;Erratum in:&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Publisher Correction: &lt;a href=&#34;https://www.nature.com/articles/s41586-021-03204-z&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;em&gt;VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours&lt;/em&gt;&lt;/a&gt;.&lt;/p&gt;
&lt;/blockquote&gt;
&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Immune surveillance against pathogens and tumours in the central nervous system is thought to be limited owing to the lack of lymphatic drainage. However, the characterization of the meningeal lymphatic network has shed light on previously unappreciated ways that an immune response can be elicited to antigens that are expressed in the brain1-3. Despite progress in our understanding of the development and structure of the meningeal lymphatic system, the contribution of this network in evoking a protective antigen-specific immune response in the brain remains unclear. Here, using a mouse model of glioblastoma, we show that the meningeal lymphatic vasculature can be manipulated to mount better immune responses against brain tumours. The immunity that is mediated by CD8 T cells to the glioblastoma antigen is very limited when the tumour is confined to the central nervous system, resulting in uncontrolled tumour growth. However, ectopic expression of vascular endothelial growth factor C (VEGF-C) promotes enhanced priming of CD8 T cells in the draining deep cervical lymph nodes, migration of CD8 T cells into the tumour, rapid clearance of the glioblastoma and a long-lasting antitumour memory response. Furthermore, transfection of an mRNA construct that expresses VEGF-C works synergistically with checkpoint blockade therapy to eradicate existing glioblastoma. These results reveal the capacity of VEGF-C to promote immune surveillance of tumours, and suggest a new therapeutic approach to treat brain tumours.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Interpreting pathways to discover cancer driver genes with Moonlight</title>
      <link>https://example.com/article/31900418/</link>
      <pubDate>Fri, 03 Jan 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/31900418/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Cancer driver gene alterations influence cancer development, occurring in oncogenes, tumor suppressors, and dual role genes. Discovering dual role cancer genes is difficult because of their elusive context-dependent behavior. We define oncogenic mediators as genes controlling biological processes. With them, we classify cancer driver genes, unveiling their roles in cancer mechanisms. To this end, we present Moonlight, a tool that incorporates multiple -omics data to identify critical cancer driver genes. With Moonlight, we analyze 8000+ tumor samples from 18 cancer types, discovering 3310 oncogenic mediators, 151 having dual roles. By incorporating additional data (amplification, mutation, DNA methylation, chromatin accessibility), we reveal 1000+ cancer driver genes, corroborating known molecular mechanisms. Additionally, we confirm critical cancer driver genes by analysing cell-line datasets. We discover inactivation of tumor suppressors in intron regions and that tissue type and subtype indicate dual role status. These findings help explain tumor heterogeneity and could guide therapeutic decisions.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis</title>
      <link>https://example.com/article/31752906/</link>
      <pubDate>Thu, 21 Nov 2019 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/31752906/</guid>
      <description>&lt;blockquote&gt;
&lt;p&gt;&lt;strong&gt;&lt;em&gt;Erratum in:&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Correction to: &lt;a href=&#34;https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-021-01386-8&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis&lt;/a&gt;.&lt;/em&gt;&lt;/p&gt;
&lt;/blockquote&gt;
&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Backgrounds:&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Long non-coding RNAs (lncRNAs) are essential factors that regulate tumor development and metastasis via diverse molecular mechanisms in a broad type of cancers. However, the pathological roles of lncRNAs in gallbladder carcinoma (GBC) remain largely unknown. Here we discovered a novel lncRNA termed lncRNA Highly expressed in GBC (lncRNA-HGBC) which was upregulated in GBC tissue and aimed to investigate its role and regulatory mechanism in the development and progression of GBC.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Methods:&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;The expression level of lncRNA-HGBC in GBC tissue and different cell lines was determined by quantitative real-time PCR. The full length of lncRNA-HGBC was obtained by 5&amp;rsquo; and 3&amp;rsquo; rapid amplification of the cDNA ends (RACE). Cellular localization of lncRNA-HGBC was detected by fluorescence in situ hybridization (FISH) assays and subcellular fractionation assay. In vitro and in vivo assays were preformed to explore the biological effects of lncRNA-HGBC in GBC cells. RNA pull-down assay, mass spectrometry, and RNA immunoprecipitation (RIP) assay were used to identify lncRNA-HGBC-interacting proteins. Dual luciferase reporter assays, AGO2-RIP, and MS2-RIP assays were performed to verify the interaction between lncRNA-HGBC and miR-502-3p.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Results:&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;We found that lncRNA-HGBC was upregulated in GBC and its upregulation could predict poor survival. Overexpression or knockdown of lncRNA-HGBC in GBC cell lines resulted in increased or decreased, respectively, cell proliferation and invasion in vitro and in xenografted tumors. LncRNA-HGBC specifically bound to RNA binding protein Hu Antigen R (HuR) that in turn stabilized lncRNA-HGBC. LncRNA-HGBC functioned as a competitive endogenous RNA to bind to miR-502-3p that inhibits target gene SET. Overexpression, knockdown or mutation of lncRNA-HGBC altered the inhibitory effects of miR-502-3p on SET expression and downstream activation of AKT. Clinically, lncRNA-HGBC expression was negatively correlated with miR-502-3p, but positively correlated with SET and HuR in GBC tissue.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Conclusions:&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Our study demonstrates that lncRNA-HGBC promotes GBC metastasis via activation of the miR-502-3p-SET-AKT cascade, pointing to lncRNA-HGBC as a new prognostic predictor and a therapeutic target.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance</title>
      <link>https://example.com/article/31636463/</link>
      <pubDate>Mon, 21 Oct 2019 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/31636463/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Natural killer (NK) cells have crucial roles in tumor surveillance. We found that tumor-infiltrating NK cells in human liver cancers had small, fragmented mitochondria in their cytoplasm, whereas liver NK cells outside tumors, as well as peripheral NK cells, had normal large, tubular mitochondria. This fragmentation was correlated with reduced cytotoxicity and NK cell loss, resulting in tumor evasion of NK cell-mediated surveillance, which predicted poor survival in patients with liver cancer. The hypoxic tumor microenvironment drove the sustained activation of mechanistic target of rapamycin-GTPase dynamin-related protein 1 (mTOR-Drp1) in NK cells, resulting in excessive mitochondrial fission into fragments. Inhibition of mitochondrial fragmentation improved mitochondrial metabolism, survival and the antitumor capacity of NK cells. These data reveal a mechanism of immune escape that might be targetable and could invigorate NK cell-based cancer treatments.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma</title>
      <link>https://example.com/article/30475349/</link>
      <pubDate>Mon, 26 Nov 2018 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/30475349/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;The efficacy of oncolytic herpes simplex virus (oHSV) is limited by rapid viral clearance by innate immune effector cells and poor intratumoral viral spread. We combine two approaches to overcome these barriers: inhibition of natural killer (NK) cells and enhancement of intratumoral viral spread. We engineered an oHSV to express CDH1, encoding E-cadherin, an adherent molecule and a ligand for KLRG1, an inhibitory receptor expressed on NK cells. In vitro, infection with this engineered virus, named OV-CDH1, induced high surface E-cadherin expression on infected glioblastoma (GBM) cells, which typically lack endogenous E-cadherin. Ectopically expressed E-cadherin enhanced the spread of OV-CDH1 by facilitating cell-to-cell infection and viral entry and reduced viral clearance by selectively protecting OV-CDH1-infected cells from KLRG1+ NK cell killing. In vivo, OV-CDH1 treatment substantially prolonged the survival in GBM-bearing mouse models, primarily because of improved viral spread rather than inhibition of NK cell activity. Thus, virus-induced overexpression of E-cadherin may be a generalizable strategy for improving cancer virotherapy.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Homeobox oncogene activation by pan-cancer DNA hypermethylation</title>
      <link>https://example.com/article/30097071/</link>
      <pubDate>Fri, 10 Aug 2018 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/30097071/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Background:&lt;/em&gt; Cancers have long been recognized to be not only genetically but also epigenetically distinct from their tissues of origin. Although genetic alterations underlying oncogene upregulation have been well studied, to what extent epigenetic mechanisms, such as DNA methylation, can also induce oncogene expression remains unknown.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Results:&lt;/em&gt; Here, through pan-cancer analysis of 4174 genome-wide profiles, including whole-genome bisulfite sequencing data from 30 normal tissues and 35 solid tumors, we discover a strong correlation between gene-body hypermethylation of DNA methylation canyons, defined as broad under-methylated regions, and overexpression of approximately 43% of homeobox genes, many of which are also oncogenes. To gain insights into the cause-and-effect relationship, we use a newly developed dCas9-SunTag-DNMT3A system to methylate genomic sites of interest. The locus-specific hypermethylation of gene-body canyon, but not promoter, of homeobox oncogene DLX1, can directly increase its gene expression.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Conclusions:&lt;/em&gt; Our pan-cancer analysis followed by functional validation reveals DNA hypermethylation as a novel epigenetic mechanism for homeobox oncogene upregulation.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing</title>
      <link>https://example.com/article/28622514/</link>
      <pubDate>Thu, 15 Jun 2017 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/28622514/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Systematic interrogation of tumor-infiltrating lymphocytes is key to the development of immunotherapies and the prediction of their clinical responses in cancers. Here, we perform deep single-cell RNA sequencing on 5,063 single T cells isolated from peripheral blood, tumor, and adjacent normal tissues from six hepatocellular carcinoma patients. The transcriptional profiles of these individual cells, coupled with assembled T cell receptor (TCR) sequences, enable us to identify 11 T cell subsets based on their molecular and functional properties and delineate their developmental trajectory. Specific subsets such as exhausted CD8+ T cells and Tregs are preferentially enriched and potentially clonally expanded in hepatocellular carcinoma (HCC), and we identified signature genes for each subset. One of the genes, layilin, is upregulated on activated CD8+ T cells and Tregs and represses the CD8+ T cell functions in vitro. This compendium of transcriptome data provides valuable insights and a rich resource for understanding the immune landscape in cancers.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Emerging Biological Principles of Metastasis</title>
      <link>https://example.com/review/28187288/</link>
      <pubDate>Thu, 09 Feb 2017 00:00:00 +0000</pubDate>
      <guid>https://example.com/review/28187288/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Metastases account for the great majority of cancer-associated deaths, yet this complex process remains the least understood aspect of cancer biology. As the body of research concerning metastasis continues to grow at a rapid rate, the biological programs that underlie the dissemination and metastatic outgrowth of cancer cells are beginning to come into view. In this review we summarize the cellular and molecular mechanisms involved in metastasis, with a focus on carcinomas where the most is known, and we highlight the general principles of metastasis that have begun to emerge.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/review/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Reviews &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer</title>
      <link>https://example.com/review/26544935/</link>
      <pubDate>Thu, 05 Nov 2015 00:00:00 +0000</pubDate>
      <guid>https://example.com/review/26544935/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Two decades of studies in multiple model organisms have established the Hippo pathway as a key regulator of organ size and tissue homeostasis. By inhibiting YAP and TAZ transcription co-activators, the Hippo pathway regulates cell proliferation, apoptosis, and stemness in response to a wide range of extracellular and intracellular signals, including cell-cell contact, cell polarity, mechanical cues, ligands of G-protein-coupled receptors, and cellular energy status. Dysregulation of the Hippo pathway exerts a significant impact on cancer development. Further investigation of the functions and regulatory mechanisms of this pathway will help uncovering the mystery of organ size control and identify new targets for cancer treatment.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/review/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Reviews &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Molecular pathways: autophagy in cancer--a matter of timing and context</title>
      <link>https://example.com/review/25165101/</link>
      <pubDate>Wed, 27 Aug 2014 00:00:00 +0000</pubDate>
      <guid>https://example.com/review/25165101/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Autophagy is an intracellular self-digestion mechanism, by which cellular components are sorted into double-membrane autophagosomes and delivered to lysosomes for degradation. Cells use autophagy to dispose of wastes and eliminate hazards, while recycling nutrients and tuning metabolism in the process. Through these functions, autophagy promotes cell fitness, genome integrity, tissue homeostasis, and cell survival and growth under stress. Both autophagy upregulation and downregulation have been found in human cancers, suggesting a complex role in tumor development. Accumulating results from autophagy-deficient mice and mouse models of human cancers have demonstrated that autophagy generally suppresses tumor initiation, but promotes tumor progression, in a manner that is dependent on timing and context and modified by specific tumorigenic events. Given the role of autophagy in facilitating tumor growth, autophagy inhibition has gained wide attention as a potential anticancer therapy. Here, we summarize relevant genetic, preclinical, and clinical studies and discuss the multifaceted role of autophagy in cancer, as well as the prospects of autophagy inhibition for cancer therapy.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/review/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Reviews &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells</title>
      <link>https://example.com/article/18355723/</link>
      <pubDate>Fri, 21 Mar 2008 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/18355723/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;We screened small molecules to identify two compounds, which we named RSL3 and RSL5, that have increased lethality in the presence of oncogenic RAS. Counter screening with biologically active compounds defined aspects of the mechanism of action for RSL3 and RSL5, such as a nonapoptotic, MEK-dependent, and iron-dependent oxidative cell death. Erastin, a previously reported compound with RAS-selective lethality, showed similar properties. RNA interference experiments targeting voltage-dependent anion channel 3 (VDAC3), a target of erastin, demonstrated that RSL5 is a scaffold that acts through VDACs to activate the observed pathway. RSL3 activated a similar death mechanism but in a VDAC-independent manner. We found that cells transformed with oncogenic RAS have increased iron content relative to their normal cell counterparts through upregulation of transferrin receptor 1 and downregulation of ferritin heavy chain 1 and ferritin light chain.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
  </channel>
</rss>
